Clopidogrel nano-emulsion (Ascendia/Lerming Pharmaceutical)

吡格雷纳米乳注射剂(Ascendia/乐明药业)

Report date: 2023/02/22 14:52:52

Base Information

Drug NameClopidogrel nano-emulsion (Ascendia/Lerming Pharmaceutical)
Drug Alias Name吡格雷纳改良型（Ascendia/乐明药业）ASD-002
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPurinergic receptor P2Y12 antagonists
TargetsPurinergic receptor P2Y12
Therapy Area/IndicationsAcute Coronary Syndrome
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesLerming Pharmaceutical(Suzhou) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesLerming Pharmaceutical(Suzhou) Co Ltd
Inactive CompaniesN/A
Active IndicationsAcute Coronary Syndrome
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A